
    
      This was a Phase 3 multicenter, open-label, safety and tolerability extension trial of 10 mg
      elobixibat daily, with possibility for dose adjustment to 5 mg daily, for 52-week Treatment
      Period in patients with CIC. A dose adjustment to 5 mg/day was allowed for the remainder of
      the trial if a patient reported unacceptable treatment-related diarrhoea that occurred within
      the first four weeks of treatment.

      The trial enrolled patients from two lead-in, double-blind efficacy trials (trial codes
      NCT01827592 and NCT01833065).
    
  